ImpediMed

03/19/2026

What can the scale miss?

Swipe to see how body composition monitoring provided deeper insight during a GLP-1–assisted weight loss program.

SOZO® with Bioimpedance Spectroscopy (BIS) offers non-invasive precision in tracking fat mass, lean mass, and fluid status — all in under 30 seconds.

Because weight alone doesn’t reflect the full picture of a patient’s health.

Learn more about precision body composition in medical weight management:
https://www.impedimed.com/weight-management/

03/17/2026

Last week, in recognition of World Lymphedema Day, AdventHealth brought patients and care teams together for a patient-focused event centered on lymphedema awareness and ongoing support.

We were proud to have our team member Melissa Searle join the event — representing ImpediMed and supporting the AdventHealth clinicians as they continue to lead survivorship care in their community.

It’s inspiring to see patients, providers, and partners come together to keep these conversations moving forward.

03/12/2026

Lymphedema doesn’t always develop during treatment. It can emerge months — or even years — later.

That’s why survivorship care shouldn’t end when treatment ends.

Subtle changes in fluid status can occur long before visible swelling appears. Monitoring across the patient care continuum allows clinicians to detect those changes earlier — and respond proactively.

From cancer centers to rehabilitation, specialty clinics, and beyond, continuity matters.

Awareness means staying engaged beyond remission.

Learn more about proactive survivorship monitoring:
https://www.impedimed.com

03/12/2026

We are grateful to see the National Lymphedema Network recognizing the clinicians serving on its Medical Advisory Committee for Lymphedema Surgery.



Clear, evidence-informed standards around surgical care are critical to improving long-term outcomes in lymphatic care — and we’re proud to see our team member Maureen McBeth contributing alongside this distinguished group.

Today, we’re shining a spotlight on the clinicians and researchers serving on the NLN Medical Advisory Committee for Lymphedema Surgery! 💜

Your expertise helps shape NLN Position Papers and strengthens how our community understands surgical options, patient selection, and long term care. Because of your leadership, patients and providers have clearer guidance, better education, and stronger standards to lean on.

Thank you for the time, care, and commitment you bring to advancing lymphatic care!

03/10/2026

This Lymphedema Awareness Month, we’re proud to spotlight Dr. Sheri Prentiss, MD, MPH — a breast cancer and lymphedema survivor whose voice continues to shape the future of survivorship care.

As both a physician and a survivor, Dr. Sheri understands the clinical realities of breast cancer — and the lived experience that follows. Her advocacy is rooted in that dual perspective: data-driven, deeply personal, and focused on improving outcomes for the patients who come after her.

Later this month, she will deliver the keynote address at the National Consortium of Breast Centers (NCoBC) 2026 Interdisciplinary Conference:
“From Diagnosis to Destiny: Transforming Trauma into Purpose in Breast Cancer Care.”

Her message reflects something we believe strongly: survivorship does not end at treatment. It evolves — and it deserves attention, intention, and earlier detection of complications like lymphedema.

We’re honored to stand alongside Dr. Sheri as she continues to elevate the patient voice and advocate for proactive care.

03/08/2026

On International Women’s Day, we recognize that women’s health is more than a moment — it’s a lifelong continuum.

From cancer survivorship to heart health, medical weight management, and wellness, women deserve care that looks at the whole body — not just one diagnosis.

For breast cancer survivors, that includes earlier recognition of complications like lymphedema. It also includes monitoring changes in fluid status, muscle mass, and overall health as treatment evolves.

Advancing women’s health means delivering real-time, personalized insight across every stage of care.

03/06/2026

Today is World Lymphedema Day.

Established in 2016 and driven by advocates around the world, March 6 is dedicated to educating the public about lymphatic diseases — including primary and secondary lymphedema — and elevating the voices of those living with them.

Lymphedema is often misunderstood. It can develop quietly and progress over time, affecting mobility, comfort, and quality of life.

Awareness is more than recognition. It is education, earlier detection, and access to care.

Today, we stand with the global community of patients, clinicians, and advocates working to make lymphatic diseases a priority in healthcare.

Learn more about World Lymphedema Day and how to get involved:https://lymphaticnetwork.org/wld/

03/04/2026

March is Lymphedema Awareness Month.

For many breast cancer survivors, lymphedema doesn’t begin with visible swelling. It begins quietly — with fluid shifts that aren’t detectable to the eye.

Approximately 1 in 5 survivors will develop lymphedema. Too often, it’s identified only after symptoms begin to interfere with mobility and daily routines. But early changes are measurable, and when they’re caught early, intervention can prevent progression.

This month, we’re focusing on education: what lymphedema is, how it develops, and why proactive monitoring matters in survivorship care.

Awareness isn’t just recognition. It’s earlier action.

Learn more: https://www.impedimed.com/patients/preventing-lymphedema/

03/02/2026

If you’re here at , come see us.

We’re joining the heart failure community this week to focus on what’s next: earlier insight, better monitoring, and data that supports action before patients decompensate.

Stop by Booth 16 to talk about:
🔎 New data shaping how risk is identified
📊 Device-based monitoring approaches
🩺 Real-world heart failure case insights

📍 Booth 16 | March 2–4 | Boston

02/28/2026

is where the heart failure community comes together to focus on what’s next: earlier insight, better monitoring, and data that supports action before patients decompensate.

Here’s what’s driving the conversation:
✅ New data shaping how risk is identified
✅ Device-based approaches to monitoring and management
✅ Practical insights from complex, real-world heart failure cases

If you’re attending, we’d love to connect and talk about where heart failure care is headed — and what’s already changing in practice.

📍 Booth 16 | March 2–4 | Boston

https://www.thtmeeting.com

02/27/2026

“We have precision oncology, precision drugs, and tailored regimens. We’re starting to see the same level of precision in lymphedema care.”

In this conversation from Living Beyond Breast Cancer’s webinar, breast surgical oncologist Dr. Monique Gary explains why monitoring fluid changes matters — not just measuring an arm with a tape measure after swelling shows up.

The goal: identify fluid shifts early, understand a patient’s individual risk, and act before visible swelling and loss of function.

🎥 Watch the clip below.

02/25/2026

We're delighted to welcome Erik Anderson to the ImpediMed Board as an independent Non-Executive Director.

Erik is a proven US MedTech leader who spent over a decade at Hologic, Inc. (NASDAQ: HOLX), where he held multiple Division President roles — including leading the $1.6B+ Breast & Skeletal Health franchise, the company's largest business unit.

His appointment is a strong signal of our commitment to growth across three fronts:

- Cancer Survivorship — Erik led the global market leader in breast screening and diagnostics, giving him deep relationships across the oncology and breast cancer survivorship ecosystem where our BCRL solution is making a real difference for patients.
- Body Composition — Hologic's Skeletal Health business includes DXA, one of the most established measures of body composition, while his leadership of Cynosure brought body contouring and wellness technologies into the MedSpa channel. This experience is directly relevant as we expand SOZO into body composition monitoring.
- US Commercial Ex*****on — With 16+ years working with US hospital systems, IDN procurement leaders, and clinical champions, Erik brings the relationships and playbook to accelerate our growth across BCRL, body composition, and heart health.

In Erik's words: "I see enormous growth potential — not just in lymphedema, where the clinical evidence and guideline support are compelling, but across survivorship care and into heart health and body composition."

We couldn't agree more. Welcome to the team, Erik.

Read the full ASX announcement: https://investors.impedimed.com/announcements/7396928